Contribute Try STAT+ Today

Despite various issues that have slowed biosimilar uptake by the U.S. health care system, usage is expected to accelerate over the next few years and the overall sales generated by these medicines are forecast to nearly triple to roughly $2.5 billion by 2024, a new analysis suggested.

The optimistic outlook reflects several factors, although some remain unsettled. A key contributor is the effort by the Food and Drug Administration to approve a growing number of biosimilars, which are nearly identical variants of pricey brand-name biologic medicines that are expected to cost less but yield the same health outcomes. So far, the agency has approved 26 such medicines.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.